Company announcementCompany-reported
What was reported
CAMBRIDGE, Mass., June 13, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 15, 2026 · Open the source ↗
What the evidence supports
Intellia Therapeutics furnished a press release to the SEC (Form 8-K, Item 7.01) about a company announcement. It shows what the company chose to disclose on that date.
What remains unknown
Claims in the release are the company's own and have not been independently verified. Furnishing a document to the SEC does not mean the SEC reviewed or endorsed it.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 15, 2026 · Open the source ↗
Press release lead paragraphCAMBRIDGE, Mass., June 13, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Jun 15, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.